Prevention of disease Archives - Page 5 of 6

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

Acceptability and effect on public and cost-effectiveness impact

BCG revaccination, M72/AS01e

Ongoing

Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.

Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines

2016

BCG revaccination, Hypothetical vaccines

The aim was to provide a summary of the modeling methodology used, the characteristics of future TB vaccines explored using modeling, and the comparative epidemiological impact of such novel vaccine profiles.

ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique

2022-2024

Ongoing

This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.

New tuberculosis vaccines: advances in clinical development and modelling

2020

We summarize the mathematical modelling literature used to inform vaccine development, focusing on models that address the epidemiologic impact of new TB vaccines. Finally,we describe the future for TB vaccines in the effort towards TB elimination

Country and target population prioritization

2023-2024

BCG revaccination, M72/AS01e

Ongoing

Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders

Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines

2022

Our study provides crucial information for implementing novel TB vaccines in specific target groups and on country specific acceptability and feasibility. Key groups for vaccine implementation in these settings were identified, and should be included in clinical trials and implementation planning.

Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa

BCG revaccination, M72/AS01e